<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>13
<FILENAME>d918922dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No. 3 to Collaboration and License Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No. 3 to Collaboration and License Agreement (this &#147;<B><I>Amendment No. </I></B><B><I>3</I></B>&#148;) is made and
effective as of December 1, 2015, by and between <B>Proteostasis Therapeutics, Inc.</B>, a corporation existing under the laws of the State of Delaware, having a place of business at 200 Technology Square, 4th Floor, Cambridge, MA 02139
(&#147;<B><I>PTI</I></B>&#148;) and <B>Astellas Pharma Inc.</B>, a Japanese corporation having its principal place of business at 5-1 Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411, Japan<B> </B>(&#147;<B><I>Astellas</I></B>&#148;). Each of
Astellas and PTI is sometimes referred to individually herein as a &#147;<B><I>Party</I></B>&#148; and collectively as the &#147;<B><I>Parties</I></B>&#148;<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to that certain Collaboration and License Agreement dated November 4, 2014 and amended on May 1, 2015 and August 5,
2015, by and between the Parties (the &#147;<B><I>Agreement</I></B>&#148;). Capitalized terms used, but not defined herein shall have the meanings ascribed to such terms in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties now wish to further amend the Agreement pursuant to the terms and conditions set forth herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, the mutual covenants contained herein and other valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Section 2.3(b) is deleted in its entirety and
replaced with the following language: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(b) <U>Hit Series</U>. Following the HTS Phase for each Project, PTI will present the results
of the HTS Phase to the JRC and the JRC will assess the results of the HTS Phase in accordance with the guideline set forth in the Research Plan (Hit Series Criteria Guideline) and the potential development path for various screened Active
Compounds. Following the presentation of the results of the HTS Phase to the JRC, Astellas may designate one or more Hit Series to be taken forward into the Optimization Phase by providing written notice to PTI no later than January 31, 2016.
Following the conclusion of the HTS Phase, if an Active Compound is not included in a Hit Series designated by Astellas to be taken forward into the Optimization Phase, it will thereafter be a Discontinued Compound and may not thereafter be
designated as part of a Hit Series.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Except as amended hereby, all other terms of the Agreement shall remain unchanged and in
full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Amendment No. 3 will be governed by, and construed in accordance with, the laws of the state of New York,
without taking into consideration any choice of law principles that would lead to the application of the laws of another jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signatures Appear on the Page Immediately Following </P> 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 3 to be executed by their duly authorized
representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="5%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="42%"></TD> 
<TD VALIGN="bottom" WIDTH="6%"></TD> 
<TD WIDTH="5%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="43%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="3"><B>ASTELLAS PHARMA INC. </B></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3"><B>PROTEOSTASIS THERAPEUTICS, INC.</B></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/Shunichiro Matsumoto</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/Meenu Chhabra</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="5"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><B></B>Name:&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">Shunichiro Matsumoto</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD> 
<TD VALIGN="top">Name:&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">Meenu Chhabra</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="5"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD> 
<TD HEIGHT="5" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">Vice President, Innovation Management<B></B></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD> 
<TD VALIGN="top"><B></B>Title: <B></B></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"><B></B>President and Chief Executive Officer</TD></TR>
</TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P> 
 
</BODY></HTML>
</TEXT>
</DOCUMENT>
